Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04213872 · ClinicalTrials.gov registry record · NA

Gene Expression, Meditative Movement, and Emotional Distress (GME)

A NA study of Cognitive Impairment, sponsored by Arizona State University.

Completed
Registry status
NA
Development phase
27
Enrollment target
1
Study location

NCT04213872 is a NA study of Cognitive Impairment that has completed, run by Arizona State University. The registered enrollment target is 27 participants, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04213872, a NA study of Cognitive Impairment, has completed, sponsored by Arizona State University.

COMPLETED
Registry status
NA
Development phase
27 participants
Enrollment target
1
Study location

Study Summary

Study Title: Gene Expression, Meditative Movement and Emotional Distress (GME) Background and Objectives: Breast cancer survivors (BCS) often report decrements in cognitive functioning. Cognitive impairment (CI) is generally understood as resulting from chemotherapy or radiation, but may also result from chronic emotional distress experienced by breast cancer patients and survivors. Meditation and exercise are both known to reduce stress, with growing evidence for the potential of each to also improve cognitive functioning in cancer patients and survivors. A Meditative Movement (MM) program (Qigong/Tai Chi Easy) offers the potential of combining both benefits of meditation and exercise for breast cancer survivors. This is a pilot study, testing the MM program to effect changes in cognitive functioning and associated symptoms/conditions such as anxiety, depression, sleep quality and using gene expression factors as biomarkers to potentially measure the molecular signature of these changes. Forty BCS will be consented and assigned to an intensive eight week MM program. Cognitive functioning and associated symptoms/conditions will be assessed before and after the 8-week MM program to examine the participants' behaviors and symptoms. Peripheral blood samples will be collected before and after the 8-week MM program and will be analyzed for gene expression changes. If successful, this study may provide preliminary data for a full powered randomized control trial if results show promise in the psycho-behavioral outcomes and genomic expression results.

Conditions Studied

Interventions

  • BEHAVIORAL Meditative Movement

Study Locations (1)

California

  • Robert and Beverly Lewis Family Cancer Care Center - Pomona

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2017-07-17
Est. Completion 2020-09-15
Phase NA

Sponsor

Arizona State University

187 total trials

What the Registry Record Tells You About NCT04213872

The ClinicalTrials.gov registry entry for NCT04213872 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (96% lower). The listed sponsor is Arizona State University, which has 187 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cognitive Impairment appearing as the primary indexed condition, and to 1 intervention - of which Meditative Movement is the first listed.

NCT04213872 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04213872 about?

NCT04213872 is a clinical study titled "Gene Expression, Meditative Movement, and Emotional Distress (GME)". Study Title: Gene Expression, Meditative Movement and Emotional Distress (GME) Background and Objectives: Breast cancer survivors (BCS) often report decrements in cognitive functioning. Cognitive impairment (CI) is generally understood as resulting from chemotherapy or radiation, but may also resu...

What is the current status of trial NCT04213872?

This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2017-07-17. Estimated completion is 2020-09-15.

What conditions does trial NCT04213872 study?

This clinical trial studies the following conditions: Cognitive Impairment.

What interventions are being tested in trial NCT04213872?

The interventions under investigation include: Meditative Movement (BEHAVIORAL).

Who is sponsoring clinical trial NCT04213872?

This trial is sponsored by Arizona State University, which has 187 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04213872 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cognitive Impairment

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.